Jeffrey A. Schwaneke - Jul 1, 2024 Form 4 Insider Report for agilon health, inc. (AGL)

Role
Chief Financial Officer
Signature
/s/ Mimi Yang, as Attorney-in-Fact
Stock symbol
AGL
Transactions as of
Jul 1, 2024
Transactions value $
$0
Form type
4
Date filed
7/3/2024, 06:56 PM
Previous filing
May 31, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction AGL Common Stock Award $0 +377K +588.72% $0.00 441K Jul 1, 2024 Direct F1, F2
transaction AGL Common Stock Award $0 +132K +29.92% $0.00 573K Jul 1, 2024 Direct F2, F3
transaction AGL Common Stock Award $0 +151K +26.32% $0.00 724K Jul 1, 2024 Direct F2, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction AGL Options (Rights to Buy) Award $0 +239K $0.00 239K Jul 1, 2024 Common Stock 239K $6.07 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Restricted stock units that vest in three equal installments on each anniversary of July 1, 2024.
F2 Includes restricted stock units.
F3 Restricted stock units that vest in four equal installments on each anniversary of July 1, 2024.
F4 Performance Stock Units may become vested subject to attainment (based on 40 trading day average closing price, exceeding twice the closing price of the Company's stock price on date of grant) and within three years from grant date.
F5 Options that vest in four equal installments on each anniversary of July 1, 2024.